Angiotensin-Converting Enzyme Inhibitor-Associated Angioedema

      Angiotensin-converting enzyme (ACE, kininase II) inhibitors reduce mortality in patients who have hypertension, congestive heart failure, and diabetic nephropathy and in patients who are at high risk for cardiovascular events [
      • The SOLVD investigators
      Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
      ,
      • Lewis E.J.
      • Hunsicker L.G.
      • Bain R.P.
      • et al.
      The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
      ,
      • Yusuf S.
      • Sleight P.
      • Pogue J.
      • et al.
      Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
      ,
      • Dahlof B.
      • Sever P.S.
      • Poulter N.R.
      • et al.
      Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
      ]. ACE inhibitor–associated angioedema is a rare, potentially life-threatening side effect of treatment with ACE inhibitors. Reactions range from mild swelling of the tongue, lips, other areas of the face, hands, feet, or bowel to life-threatening airway compromise. Given that 35 to 40 million people worldwide are currently taking ACE inhibitors, the number of people at risk for this side effect is substantial.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Immunology and Allergy Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • The SOLVD investigators
        Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        N Engl J Med. 1991; 325: 293-302
        • Lewis E.J.
        • Hunsicker L.G.
        • Bain R.P.
        • et al.
        The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
        N Engl J Med. 1993; 329: 1456-1462
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • et al.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • et al.
        Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Agah R.
        • Bandi V.
        • Guntupalli K.K.
        Angioedema: the role of ACE inhibitors and factors associated with poor clinical outcome.
        Intensive Care Med. 1997; 23: 793-796
        • Cicardi M.
        • Zingale L.C.
        • Bergamaschini L.
        • et al.
        Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment.
        Arch Intern Med. 2004; 164: 910-913
        • Kostis J.B.
        • Kim H.J.
        • Rusnak J.
        • et al.
        Incidence and characteristics of angioedema associated with enalapril.
        Arch Intern Med. 2005; 165: 1637-1642
        • Schmidt T.D.
        • McGrath K.M.
        Angiotensin-converting enzyme inhibitor angioedema of the intestine: a case report and review of the literature.
        Am J Med Sci. 2002; 324: 106-108
        • Hill M.D.
        • Buchan A.M.
        Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
        CMAJ. 2005; 172: 1307-1312
        • Slater E.E.
        • Merrill D.D.
        • Guess H.A.
        • et al.
        Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition.
        JAMA. 1988; 260: 967-970
        • Gabb G.M.
        • Ryan P.
        • Wing L.M.
        • et al.
        Epidemiological study of angioedema and ACE inhibitors.
        Aust N Z J Med. 1996; 26: 777-782
        • Brown N.J.
        • Ray W.A.
        • Snowden M.
        • et al.
        Black Americans have an increased rate of angiotensin converting enzyme inhibitor–associated angioedema.
        Clin Pharmacol Ther. 1996; 60: 8-13
        • Agostoni A.
        • Cicardi M.
        • Cugno M.
        • et al.
        Angioedema due to angiotensin-converting enzyme inhibitors.
        Immunopharmacology. 1999; 44: 21-25
        • Nielsen E.W.
        • Gramstad S.
        Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate.
        Acta Anaesthesiol Scand. 2006; 50: 120-122
        • Warrier M.R.
        • Copilevitz C.A.
        • Dykewicz M.S.
        • et al.
        Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.
        Ann Allergy Asthma Immunol. 2004; 92: 573-575
      1. Icatibant. HOE 140, JE 049, JE049.
        Drugs R D. 2004; 5: 343-348
        • Cockcroft J.R.
        • Sciberras D.G.
        • Goldberg M.R.
        • et al.
        Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
        J Cardiovasc Pharmacol. 1993; 22: 579-584
        • Carey R.M.
        • Wang Z.Q.
        • Siragy H.M.
        Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function.
        Hypertension. 2000; 35 ([Review. 92 refs.]): 155-163
        • Campbell D.J.
        • Krum H.
        • Esler M.D.
        Losartan increases bradykinin levels in hypertensive humans.
        Circulation. 2005; 111: 315-320
        • Johnsen S.P.
        • Jacobsen J.
        • Monster T.B.
        • et al.
        Risk of first-time hospitalization for angioedema among users of ACE inhibitors and angiotensin receptor antagonists.
        Am J Med. 2005; 118: 1428-1429
        • Sica D.A.
        The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?.
        J Clin Hypertens (Greenwich). 2003; 5: 159-167
        • Kostis J.B.
        • Packer M.
        • Black H.R.
        • et al.
        Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
        Am J Hypertens. 2004; 17: 103-111
        • Gibbs C.R.
        • Lip G.Y.
        • Beevers D.G.
        Angioedema due to ACE inhibitors: increased risk in patients of African origin.
        Br J Clin Pharmacol. 1999; 48 ([see comments]): 861-865
        • Morimoto T.
        • Gandhi T.K.
        • Fiskio J.M.
        • et al.
        An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors.
        J Eval Clin Pract. 2004; 10: 499-509
        • Woo K.S.
        • Norris R.M.
        • Nicholls G.
        Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities).
        Am J Cardiol. 1995; 75: 967-968
        • Abbosh J.
        • Anderson J.A.
        • Levine A.B.
        • et al.
        Angiotensin converting enzyme inhibitor–induced angioedema more prevalent in transplant patients.
        Ann Allergy Asthma Immunol. 1999; 82: 473-476
        • Brown N.J.
        • Snowden M.
        • Griffin M.R.
        Recurrent angiotensin-converting enzyme inhibitor–associated angioedema.
        JAMA. 1997; 278: 232-233
        • Gainer J.V.
        • Morrow J.D.
        • Loveland A.
        • et al.
        Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
        N Engl J Med. 1998; 339: 1285-1292
        • Schapira M.
        • Silver L.D.
        • Scott C.F.
        • et al.
        Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.
        N Engl J Med. 1983; 308: 1050-1054
        • Han E.D.
        • MacFarlane R.C.
        • Mulligan A.N.
        • et al.
        Increased vascular permeability in C1 inhibitor–deficient mice mediated by the bradykinin type 2 receptor.
        J Clin Invest. 2002; 109: 1057-1063
        • Moreau M.E.
        • Dubreuil P.
        • Molinaro G.
        • et al.
        Expression of metallopeptidases and kinin receptors in swine oropharyngeal tissues: effects of angiotensin I–converting enzyme inhibition and inflammation.
        J Pharmacol Exp Ther. 2005; 315: 1065-1074
        • Nussberger J.
        • Cugno M.
        • Amstutz C.
        • et al.
        Plasma bradykinin in angio-oedema.
        Lancet. 1998; 351: 1693-1697
        • Molinaro G.
        • Cugno M.
        • Perez M.
        • et al.
        Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.
        J Pharmacol Exp Ther. 2002; 303: 232-237
        • Emanueli C.
        • Grady E.F.
        • Madeddu P.
        • et al.
        Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P.
        Hypertension. 1998; 31: 1299-1304
        • Sulpizio A.C.
        • Pullen M.A.
        • Edwards R.M.
        • et al.
        The effect of acute angiotensin-converting enzyme and neutral endopeptidase 24.11 inhibition on plasma extravasation in the rat.
        J Pharmacol Exp Ther. 2004; 309: 1141-1147
        • Kopp U.C.
        • Farley D.M.
        • Smith L.A.
        Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P.
        Am J Physiol. 1997; 272: R2009-R2016
        • Campos M.M.
        • Calixto J.B.
        Neurokinin mediation of edema and inflammation.
        Neuropeptides. 2000; 34: 314-322
        • Moreau M.E.
        • Garbacki N.
        • Molinaro G.
        • et al.
        The kallikrein-kinin system: current and future pharmacological targets.
        J Pharmacol Sci. 2005; 99: 6-38
        • Blais C.J.
        • Rouleau J.L.
        • Brown N.J.
        • et al.
        Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor–associated angioedema.
        Immunopharmacology. 1999; 43: 293-302
        • Ersahin C.
        • Simmons W.H.
        Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation.
        J Cardiovasc Pharmacol. 1997; 30: 96-101
        • Kim K.S.
        • Kumar S.
        • Simmons W.H.
        • et al.
        Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor–treated humans.
        J Pharmacol Exp Ther. 2000; 292: 295-298
        • Adam A.
        • Cugno M.
        • Molinaro G.
        • et al.
        Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors.
        Lancet. 2002; 359: 2088-2089
        • Cyr M.
        • Lepage Y.
        • Blais Jr., C.
        • et al.
        Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma.
        Am J Physiol Heart Circ Physiol. 2001; 281: H275-H283
        • Duan Q.L.
        • Nikpoor B.
        • Dube M.P.
        • et al.
        A variant in XPNPEP2 is associated with angioedema induced by angiotensin I–converting enzyme inhibitors.
        Am J Hum Genet. 2005; 77: 617-626
        • Russell J.S.
        • Chi H.
        • Lantry L.E.
        • et al.
        Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts.
        Peptides. 1996; 17: 1397-1403
        • Lefebvre J.
        • Murphey L.J.
        • Hartert T.V.
        • et al.
        Dipeptidyly peptidase IV activity in patients with ACE-inhibitor—associated angioedema.
        Hypertension. 2002; 39: 460-464
        • Sprinkle T.J.
        • Stone A.A.
        • Venema R.C.
        • et al.
        Assignment of the membrane-bound human aminopeptidase P gene (XPNPEP2) to chromosome Xq25.
        Genomics. 1998; 50: 114-116
        • Sprinkle T.J.
        • Caldwell C.
        • Ryan J.W.
        Cloning, chromosomal sublocalization of the human soluble aminopeptidase P gene (XPNPEP1) to 10q25.3 and conservation of the putative proton shuttle and metal ligand binding sites with XPNPEP2.
        Arch Biochem Biophys. 2000; 378: 51-56
        • Abbott C.A.
        • Baker E.
        • Sutherland G.R.
        • et al.
        Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene.
        Immunogenetics. 1994; 40: 331-338